Part of the issue may be the large size of the antibody being unable to penetrate solid tumours, whereas shrinking the tumour with other approaches before immune checkpoint immunotherapy could avoid this.
Part of the issue may be the large size of the antibody, whereas shrinking the tumour with other approaches before immune checkpoint immunotherapy could avoid this. This antibody is being unable to penetrate solid tumours.